8-K: Vaxart Urges Stockholders to Approve Reverse Stock Split to Avoid Nasdaq Delisting, Addresses Investor Concerns

Vaxart, Inc. is urging stockholders to vote for a reverse stock split proposal by June 1, 2025, to regain Nasdaq compliance and addresses key investor concerns regarding financing, pipeline progress, and market dynamics.

Summary

• Vaxart adjourned its Annual Meeting to June 2, 2025, to allow more time for stockholders to vote on a reverse stock split proposal, which is crucial for regaining Nasdaq compliance and avoiding potential delisting.
• The company faces a Nasdaq compliance deadline of June 30, 2025, to meet the minimum bid price requirement.
• The Board has committed to a maximum reverse stock split ratio of 1-for-20, a reduction from the previously proposed 1-for-50, based on investor feedback.
• Vaxart plans to call a special meeting to proportionally reduce authorized shares after the reverse stock split is implemented, addressing investor concerns about potential dilution.
• The company raised $40 million through an underwritten offering in June 2024, extending its cash runway to over 12 months, as its previous runway was less than six months.
• The $460.7 million BARDA Project NextGen award is a cost-reimbursable contract, meaning funds are primarily released as costs are incurred for the COVID-19 Phase 2b trial and fixed fees, and is not sufficient to fund all company operations and other product candidates.
• Management confirmed personal investment in Vaxart shares, including recent purchases by CEO Steven Lo, and believes the current share price undervalues the company's oral pill vaccine platform.
• Vaxart is actively exploring business development opportunities and partnerships, but believes more clinical data from programs like norovirus are needed to advance discussions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While management is actively addressing investor concerns and making efforts to maintain Nasdaq listing and advance programs, the underlying issues of low share price, delisting risk, and ongoing capital needs indicate significant challenges. The transparency and responsiveness to investor feedback are positive, but the core financial and market position remains precarious.

Positives

• The Board committed to a lower maximum reverse stock split ratio of 1-for-20 (compared to 1-for-50 previously) based on investor feedback.
• The company plans to proportionally reduce authorized shares after the reverse stock split, addressing dilution concerns raised by investors.
• A successful $40 million underwritten offering in June 2024 extended the company's cash runway to over 12 months, providing financial stability for ongoing operations.
• The stop work order for the BARDA-funded Project NextGen award has been lifted, allowing progress on the COVID-19 Phase 2b trial.
• Management, including CEO Steven Lo, has invested personal funds in the company, demonstrating confidence in Vaxart's prospects.
• The company is advancing its norovirus clinical program and preclinical human papillomavirus (HPV) and avian influenza programs.

Negatives

• Vaxart is at risk of delisting from Nasdaq due to not meeting the minimum bid price requirement, necessitating a reverse stock split.
• The need for a reverse stock split indicates a sustained low share price, which can be a negative signal to the market.
• The $460.7 million BARDA award is structured as a cost-reimbursable contract and is not sufficient to fund all company operations, implying a continued need for additional capital raises.
• Partnership discussions require more clinical data from programs like norovirus, indicating potential delays in securing non-dilutive funding and commercialization.

Risks

• Potential delisting from Nasdaq if the company does not regain compliance with the minimum bid price requirement by the June 30, 2025 deadline.
• No assurance that an appeal to Nasdaq regarding a delisting determination would be successful.
• Biotechnology development is a costly, capital-intensive endeavor, requiring ongoing financing through equity or other means.
• Reliance on equity financing as a key component of the financing strategy, which can lead to dilution.
• Uncertainty regarding the natural recovery of the share price before the Nasdaq compliance deadline, which could still necessitate the reverse stock split.
• The BARDA award is cost-reimbursable, meaning funds are not fully accessible upfront and are tied to incurred costs and fixed fees, which are typically low single-digit percentages.
• The company cannot control short selling activities, which may impact share price.
• More data from programs like norovirus are needed to advance partnership discussions, potentially delaying non-dilutive funding opportunities.

Future Outlook

Vaxart's primary focus is on regaining Nasdaq compliance through a potential reverse stock split by the June 30, 2025 deadline. The company aims to drive future value through data readouts from its norovirus and COVID-19 programs and continues to explore business development opportunities, though further clinical data is needed to advance partnership discussions. They also plan to call a special meeting to reduce authorized shares proportionally after the reverse stock split is implemented.

Management Comments

• "We appreciate the continued interest from our passionate and loyal stockholder base." Steven Lo, Chief Executive Officer.
• "Understanding their concerns and directly addressing their most frequently asked questions, we are hopeful that this additional information will be helpful as they consider the reverse stock split proposal." Steven Lo, Chief Executive Officer.
• "The Board believes it's crucial for stockholders to have more time to vote, especially considering the potential delisting from Nasdaq."
• "The Company is focused on moving its programs forward to drive additional potential value-creating catalysts including data readouts from norovirus and COVID-19, which it believes can drive investor interest."
• "While the Company cannot control short selling, it reminds stockholders that a reverse stock split does not inherently increase shorting or cause dilution."
• "Given the fast-approaching June 30th Nasdaq compliance deadline, Vaxart believes the approval allowing the Board to effect a reverse split is the best chance at regaining Nasdaq compliance."
• "The Board and Management considered it a prudent decision to raise $40 million, which enabled the Company to extend its cash runway over 12 months through this important offering."
• "We believe that our norovirus and other programs have potential with a partner, however, at this time more data from these programs are needed to further advance our discussions with potential partners."
• "Management continues to believe that the current share price does not accurately reflect the full value of its oral pill vaccine platform and product candidates."

Industry Context

Vaxart operates in the highly capital-intensive biotechnology sector, specifically focusing on oral recombinant vaccines. The need for frequent capital raises and the challenges of maintaining Nasdaq listing requirements due to low stock prices are common issues for clinical-stage biotech companies that are pre-revenue or have limited revenue. The company's engagement with BARDA (Biomedical Advanced Research and Development Authority) for Project NextGen highlights its involvement in government-funded pandemic preparedness initiatives, a significant trend in the biotech industry post-COVID-19. The pursuit of partnerships for programs like norovirus is also a standard strategy for smaller biotechs to secure non-dilutive funding and leverage larger pharmaceutical companies' resources for late-stage development and commercialization.

Comparison to Industry Standards

• Biotech companies typically raise capital through a combination of equity investors, strategic partners, and grants, which aligns with Vaxart's financing strategy (equity offerings, BARDA award, seeking partnerships).
• Effecting a reverse stock split without changing authorized shares is not uncommon in the biotech industry for Nasdaq compliance, although Vaxart is proposing a proportional reduction based on investor feedback, which is a positive adaptation.
• The structure of BARDA awards as cost-reimbursable contracts with single-digit fixed fees is typical for government R&D contracts, meaning they are not upfront cash infusions but rather funding for specific project execution.

Corporate Governance

Stakeholder Impact

• Shareholders are directly impacted by the reverse stock split proposal, potential delisting, and ongoing capital raises. The proportional reduction in authorized shares aims to address their dilution concerns. Management's personal investment and responsiveness to FAQs are intended to reassure them.
• Employees are indirectly impacted by the company's financial stability and ability to advance programs, with an employee stock purchase plan mentioned.
• Future customers and patients are indirectly impacted by the company's ability to fund and advance its vaccine candidates (norovirus, COVID-19, flu, HPV, avian influenza).
• Nasdaq is directly involved in the compliance requirements and potential delisting process.
• BARDA is a key partner and funding source for the COVID-19 program.

Next Steps

• Stockholders are urged to vote FOR the reverse stock split proposal by 11:59 p.m. Eastern Time on June 1, 2025.
• The Annual Meeting of Stockholders is scheduled for Monday, June 2, 2025.
• If Proposal No. 2 (reverse stock split) is approved, the exact ratio will be determined near the Nasdaq compliance deadline (June 30, 2025).
• The company will call a special meeting to reduce authorized shares proportionally shortly after implementing the reverse stock split.
• Continue to move programs forward to drive value-creating catalysts, including data readouts from norovirus and COVID-19.
• Continue exploring business development opportunities and partnerships.
• Stockholders are encouraged to sign up for real-time email alerts and read SEC filings for official information.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, Reverse Stock Split, Nasdaq Compliance, Delisting Risk, Biotechnology, Oral Vaccine, Norovirus, COVID-19 Vaccine, BARDA Award, Project NextGen, Capital Raise, Equity Financing, Clinical Trials, Shareholder Meeting, Biotech Investment, Pharmaceutical Development